Business

Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced its participation in a drug development panel at Fierce Biotech Week taking place October 7-9, 2025 in Boston, MA. Panel Title:How Biotechs are Leveraging Artificial Intelligence (AI)/Machine Learning (ML) to Drive Efficiency and ROIPresenter: Marie

articleSagimet Biosciences Inc. - Series ASeptember 24, 20252/company/sagimet-biosciences-inc-series-a-common-stock/news/sagimet-biosciences-announces-upcoming-panel-110000404
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

About this update from Sagimet Biosciences Inc. - Series A

[{"type":"image","alt":"Sagimet Biosciences Inc.","displaySize":"","headline":null,"caption":"Sagimet Biosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AmJDa7oTdvowtNmgiL7OTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25","width":300,"height":110}},"lazy":false},{"type":"text","content":"SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced its participation in a drug development panel at Fierce Biotech Week taking place October 7-9, 2025 in Boston, MA.","length":364,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:20%;width:20%;min-width:20%;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Panel Title:","length":12,"tagName":"p","attribs":{}}]},{"style":"max-width:80%;width:80%;min-width:80%;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"How Biotechs are Leveraging Artificial Intelligence (AI)/Machine Learning (ML) to Drive Efficiency and ROI","length":106,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Presenter:","length":10,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Marie O’Farrell, Ph.D., Senior Vice President of Research and Development, Sagimet Biosciences","length":99,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Date and time:","length":14,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Thursday, October 9, 2025, 11.15am ET","length":37,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Pa...

More updates from Sagimet Biosciences Inc. - Series A

Sagimet Biosciences Inc.drug developmentmetabolic dysfunctionbiopharmaceutical companySagimet Biosciencesdevelopmentliver fibrosissteatohepatitisclinical trials